Valion Bio (VBIO) Interim CEO Zikria Dean Receives Award

What Happened

• Zikria Dean, Interim CEO and Director of Valion Bio, received a grant of 50,000 Restricted Stock Units (RSUs) reported on Sep 22, 2026. The Form 4 shows an acquisition-type derivative award at $0.00 per unit (no cash paid at grant). Each RSU converts into one share of common stock upon vesting.

Key Details

• Transaction date: 2026-09-22; filing date: 2026-09-24.
• Award: 50,000 RSUs; grant price reported: $0.00 (no cash exchanged at grant).
• Vesting: One-fourth (1/4) of the RSUs vest quarterly; first vesting date is Dec 22, 2026.
• Reverse split: Numbers reflect a 1-for-25 reverse stock split effective Aug 31, 2026.
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing shows report filed Sep 24, 2026; no late-filing flag noted in the provided data.

Context

• These RSUs are a derivative compensation award that will convert into common shares as they vest; they are not an open-market purchase or sale. No immediate sale or exercise occurred. Such grants are typically part of executive compensation and do not by themselves indicate buying or selling of stock by the insider.